Renalytix PLC
LSE:RENX
Renalytix PLC
LSE:RENX
Price:
23.5 GBX
-4.08%
Updated:
May 16, 2024
EV/S
Enterprise Value to Sales
Enterprise Value to Sales
-540
Current
-1 164.1
Median
2.5
Industry
Higher
than median
Lower
than industry value
Enterprise Value to Sales (EV/S) ratio is a valuation multiple that compares the enterprise value (EV) of a company to its revenues. The EV/S multiple gives investors a quantifiable metric of how to value a company based on its sales while taking account of both the company's equity and debt.
EV/S
=-540
Enterprise Value
/
-1.4B
Revenue
3.4m
All Countries
| Market Cap | EV/S | ||||
|---|---|---|---|---|---|
| UK |
|
Renalytix PLC
LSE:RENX
|
29m GBP | -540 | |
| US |
|
Veeva Systems Inc
NYSE:VEEV
|
34.1B USD | 12.7 | |
| US |
|
Cerner Corp
NASDAQ:CERN
|
27.9B USD | 4.9 | |
| US |
|
Change Healthcare Inc
NASDAQ:CHNG
|
9B USD | 3.8 | |
| AU |
|
Pro Medicus Ltd
ASX:PME
|
12.5B AUD | 84.7 | |
| JP |
|
M3 Inc
TSE:2413
|
1.1T JPY | 4 | |
| US |
|
Inspire Medical Systems Inc
NYSE:INSP
|
4.7B USD | 6.5 | |
| US |
|
Doximity Inc
NYSE:DOCS
|
4.4B USD | 8 | |
| SE |
|
Sectra AB
STO:SECT B
|
45.5B SEK | 27.4 | |
| US |
|
Vocera Communications Inc
NYSE:VCRA
|
2.8B USD | 11.3 | |
| US |
|
Goodrx Holdings Inc
NASDAQ:GDRX
|
2.7B USD | 3.7 |
EV/S Forward Multiples
Forward EV/S multiple is a version of the EV/S ratio that uses forecasted revenue for the EV/S calculation. 1-Year, 2-Years, and 3-Years forwards use revenue forecasts for 1, 2, and 3 years ahead, respectively.
1-Year Forward
EV/S
-3.6
2-Years Forward
EV/S
-1.8
3-Years Forward
EV/S
-1
You don't have any saved screeners yet
